Pharmaceutical giant Eli Lilly & Company has demonstrated continued momentum beyond its current blockbuster products, announcing a trio of significant developments this week. These strategic moves, ranging from compelling clinical data to a targeted licensing deal, collectively reinforce the company’s long-term growth strategy and operational foundation for the coming years.
This operational progress builds upon a robust financial outlook. On February 4, the corporation provided a revenue forecast for the full year 2026, projecting sales between $80 and $83 billion. While its highly sought-after metabolic therapies remain the primary growth engine, the latest announcements highlight a productive and broadening research pipeline.
Strategic Acquisition to Broaden Immunology Reach
The week’s news was capped by a strategic licensing agreement with CSL Limited. For an upfront payment of $100 million, Eli Lilly secured the rights to clazakizumab, a monoclonal antibody targeting interleukin-6. CSL will continue developing the drug for cardiovascular events in kidney patients, while Lilly plans to explore its application in other autoimmune and inflammatory diseases. This deal exemplifies a deliberate effort to diversify the company’s portfolio beyond the current spotlight on weight-loss medications.
Should investors sell immediately? Or is it worth buying Eli Lilly?
Sustained Efficacy in Crohn’s Disease Treatment
In the immunology sector, new long-term data from the VIVID-2 study for Omvoh (mirikizumab) in Crohn’s disease showed highly sustainable results. Over 90% of patients who achieved steroid-free remission after one year maintained this status throughout the entire three-year study period. Furthermore, the data indicated low rates of surgeries and hospitalizations, underscoring the therapy’s potential for effective long-term disease management.
Promising Combination Therapy for Psoriasis and Obesity
Particularly promising results came from the Phase 3b TOGETHER-PsO study, released on February 18. The investigation evaluated a combination of the psoriasis drug Taltz and the obesity treatment Zepbound (tirzepatide) in patients suffering from both moderate-to-severe plaque psoriasis and obesity. The combination therapy proved significantly superior to Taltz alone after 36 weeks, with improvements measured in both skin clearance and weight reduction. These findings point to a potential novel, comprehensive treatment approach for this specific patient population.
Through this combination of organic pipeline progress and strategic external licensing, Eli Lilly is strengthening the fundamental platform needed to achieve its ambitious revenue target of over $80 billion by 2026.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from February 20 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 20.
Eli Lilly: Buy or sell? Read more here...
